A former Johnson & Johnson executive’s allegations that the drug company overpaid for prescription drug benefits are ...

Argus Research analyst David Toung maintained a Buy rating on Johnson & Johnson (JNJ – Research Report) yesterday. The company’s shares ...

We recently compiled a list of the 10 Best Diversified Dividend Stocks To Buy Now. In this article, we are going to take a ...

On the company’s Q4 earnings call where an eyepopping $88.8 billion in full-year sales were revealed, leaders shifted focus ...

Spravato is now the first-ever stand-alone therapy for treatment-resistant depression, and is on its way to becoming a ...

WASHINGTON – House Republicans gave Mike Johnson the speaker's gavel on Friday – along with a warning. Nine GOP lawmakers at first either abstained from voting for Johnson or voted for a ...

S&P Global Ratings placed Johnson & Johnson on CreditWatch with negative implications, citing its nearly $15 billion deal to acquire mental-illness drug developer Intra-Cellular Therapies.

Pharmaceutical giants have recently shown new enthusiasm for mental-health treatments with vast but unrealized promise.

Johnson & Johnson will spend more than $14 billion to delve further into the treatment of central nervous system disorders by ...

Johnson & Johnson acquires Intra-Cellular Therapies for $14.6 billion. The biggest driver was the rights Caplyta which has ...

“This acquisition further differentiates our portfolio, serves as a strategic near- and long-term growth catalyst for Johnson & Johnson and offers compelling value to patients, health systems and ...

Vin Diesel and Dwayne Johnson came face to face at the 2025 Golden Globes when Diesel took the stage to present the prize for cinematic and box office achievement to “Wicked.” Diesel took a ...